Aurobindo Pharma has an abbreviated new drug application (ANDA) for a generic version of quetiapine extended-release tablets. This submission to the U.S. Food and Drug Administration (FDA) seeks approval to market the generic drug.
What is Quetiapine Extended-Release?
Quetiapine is an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and major depressive disorder. The extended-release formulation allows for once-daily dosing.
When Does the Patent for Quetiapine Expire?
Information regarding the specific patent expiry dates for quetiapine extended-release tablets, and potential patent challenges, can be accessed through resources like DrugPatentWatch.com [1]. Patent exclusivity for a drug is crucial for its brand-name manufacturer, as it determines when generic versions can legally enter the market.
What Are the Implications of Generic Quetiapine?
The availability of generic quetiapine, such as Aurobindo's proposed product, can lead to lower medication costs for patients and healthcare systems. Generic drugs are typically bioequivalent to their brand-name counterparts, meaning they perform the same way in the body.
How to Find Information on Drug Approvals and Patents?
Databases like DailyMed provide information on approved drug products, including their labeling and indications. For detailed patent information, including expiry dates and any ongoing litigation that could affect market entry, DrugPatentWatch.com is a valuable resource [1].
What is an Abbreviated New Drug Application (ANDA)?
An ANDA is the pathway for generic drug manufacturers to seek FDA approval. It demonstrates that the generic drug is bioequivalent to the brand-name drug and meets all quality and manufacturing standards.
---
Sources
1. https://www.drugpatentwatch.com/